Mark Shackleton
Overview
Explore the profile of Mark Shackleton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
7233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Woollett A, Duncan J, Voskoboynik M, Shackleton M, Dooley M, Blum R, et al.
Contemp Clin Trials Commun
. 2023 Jan;
32:101072.
PMID: 36712185
Background: Participation in clinical trials is linked to improved patient outcomes. Despite this, most trial participants either reside in, or are treated in metropolitan areas. TrialHub developed hub-and-spoke models to...
12.
Jobson D, Roffey B, Best R, Button-Sloan A, Cossio D, Evans S, et al.
BMJ Open
. 2023 Jan;
12(9):e062139.
PMID: 36691164
Introduction: Australia has the highest incidence of melanoma in the world with variable care provided by a diverse range of clinicians. Clinical quality registries aim to identify these variations in...
13.
Huo C, Gunadasa I, Gkolia P, Shackleton M, Hunn M
Melanoma Res
. 2022 Dec;
33(1):58-65.
PMID: 36545922
Immunotherapy with T-cell checkpoint inhibitors have changed the treatment landscape for patients with melanoma brain metastases (MBMs), offering increased survival compared with historical outcomes. We sought to identify clinical features...
14.
Yan M, Adler N, Wolfe R, Pan Y, Chamberlain A, Kelly J, et al.
Asia Pac J Clin Oncol
. 2022 Dec;
19(4):566-573.
PMID: 36540019
Background: Recommendations for surveillance imaging for resected melanoma vary considerably. This study examined the utility of imaging in patients with a high-risk primary melanoma undergoing a protocolized imaging schedule. Methods:...
15.
Wang C, Zoungas S, Yan M, Wolfe R, Haydon A, Shackleton M, et al.
Cardiooncology
. 2022 Dec;
8(1):23.
PMID: 36461057
Background: Immune checkpoint inhibitors (ICI) are associated with immune-mediated adverse effects, potentially involving any organ. ICI has also been associated with an increased risk of cardiovascular disease in cancer populations....
16.
Gangoda L, Schenk R, Tai L, Szeto P, Cheung J, Strasser A, et al.
Cell Death Dis
. 2022 Apr;
13(4):301.
PMID: 35379799
No abstract available.
17.
Yan M, Adler N, Pan Y, Chamberlain A, Kelly J, Yap K, et al.
J Surg Oncol
. 2022 Mar;
125(8):1312-1317.
PMID: 35262187
Background: The yield of baseline imaging in patients presenting with higher risk primary tumours, at least American Joint Committee on Cancer 8th edition stage IIC or III melanoma, is unclear....
18.
Wong S, Raleigh J, Callahan J, Vergara I, Ftouni S, Hatzimihalis A, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-14.
PMID: 35172485
Purpose: Circulating tumor DNA (ctDNA) allows noninvasive disease monitoring across a range of malignancies. In metastatic melanoma, the extent to which ctDNA reflects changes in metabolic disease burden assessed by...
19.
Dow E, Freimund A, Smith K, Hicks R, Jurcevic P, Shackleton M, et al.
JCO Precis Oncol
. 2022 Jan;
5:1001-1012.
PMID: 34994626
Noninvasive prenatal testing (NIPT) is a screening test for fetal chromosomal aneuploidy using cell-free DNA derived from maternal blood. It has been rapidly accepted into obstetric practice because of its...
20.
Wang W, Smith J, Carlino M, Burmeister B, Pinkham M, Fogarty G, et al.
Clin Transl Radiat Oncol
. 2021 Aug;
30:95-99.
PMID: 34458597
Background: Concurrent treatment with BRAF inhibitors and palliative radiation therapy (RT) could be associated with increased toxicity, especially skin toxicity. Current Eastern Cooperative Oncology Group (ECOG) consensus guideline recommend ceasing...